Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Revenue

Karyopharm Therapeutics had revenue of $140.46M in the twelve months ending March 31, 2024, down -5.16% year-over-year. Revenue in the quarter ending March 31, 2024 was $33.13M, a -14.40% decrease year-over-year. In the year 2023, Karyopharm Therapeutics had annual revenue of $146.03M, a decrease of -7.03%.

• Revenue (ttm): $140.46M
• Revenue Growth: -5.16%
• P/S Ratio: 0.71
• Revenue / Employee: $432,188
• Employees: 325
• Market Cap: 99.69M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	146.03M	-11.04M	-7.03%
Dec 31, 2022	157.07M	-52.75M	-25.14%
Dec 31, 2021	209.82M	101.73M	94.12%
Dec 31, 2020	108.09M	67.19M	164.31%
Dec 31, 2019	40.89M	10.56M	34.80%
Dec 31, 2018	30.34M	28.73M	1,790.09%
Dec 31, 2017	1.61M	1.45M	942.21%
Dec 31, 2016	154.00K	-96.00K	-38.40%
Dec 31, 2015	250.00K	21.00K	9.17%
Dec 31, 2014	229.00K	-158.00K	-40.83%
Dec 31, 2013	387.00K	-247.00K	-38.96%
Dec 31, 2012	634.00K	482.00K	317.11%
Dec 31, 2011	152.00K	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.